{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T09:36:24Z","timestamp":1785576984917,"version":"3.56.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.ijtb.2023.04.011","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T06:54:28Z","timestamp":1681196068000},"page":"S110-S116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["Update on drug-resistant pulmonary tuberculosis treatment in hemodialysis patients"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8564-7430","authenticated-orcid":false,"given":"Jonny","family":"Jonny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramitha Dwiputri","family":"Saraswati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8303-5484","authenticated-orcid":false,"given":"Bunga Pinandhita","family":"Ramadhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enda Cindylosa","family":"Sitepu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taufiq Fredrik","family":"Pasiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijtb.2023.04.011_bib1","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-019-1452-0","article-title":"Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countries","volume":"17","author":"Ragonnet","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.ijtb.2023.04.011_bib2","series-title":"Global Tuberculosis Report 2021 [Internet]","year":"2021"},{"issue":"7","key":"10.1016\/j.ijtb.2023.04.011_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002595","article-title":"Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies","volume":"15","author":"Alipanah","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.ijtb.2023.04.011_bib4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10157-018-1641-8","article-title":"Clinical epidemiology of infectious disease among patients with chronic kidney disease","volume":"23","author":"Ishigami","year":"2019","journal-title":"Clinical and Experimental Nephrology"},{"key":"10.1016\/j.ijtb.2023.04.011_bib5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ijid.2022.05.046","article-title":"Tuberculosis incidence in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"122","author":"Alemu","year":"2022","journal-title":"International Journal of Infectious Diseases"},{"issue":"2","key":"10.1016\/j.ijtb.2023.04.011_bib6","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3109\/0886022X.2015.1128290","article-title":"Incidence of tuberculosis is high in chronic kidney disease patients in South East England and drug resistance common","volume":"38","author":"Ostermann","year":"2016","journal-title":"Ren Fail"},{"issue":"4","key":"10.1016\/j.ijtb.2023.04.011_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jinf.2018.02.009","article-title":"Development and validation of a prognostic score to predict tuberculosis mortality","volume":"77","author":"Nguyen","year":"2018","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.ijtb.2023.04.011_bib8","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4010-7","article-title":"Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease","volume":"19","author":"Saito","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.ijtb.2023.04.011_bib9","doi-asserted-by":"crossref","first-page":"590","DOI":"10.5588\/ijtld.22.0263","article-title":"WHO drug-resistant TB guidelines 2022: what is new?","volume":"26","author":"Migliori","year":"2022","journal-title":"International Journal of Tuberculosis and Lung Disease. International Union Against Tuberculosis and Lung Disease"},{"key":"10.1016\/j.ijtb.2023.04.011_bib10","series-title":"Rapid Communication: Key Changes to the Treatment of Drug-Resistant Tuberculosis [Internet]","year":"2022"},{"key":"10.1016\/j.ijtb.2023.04.011_bib11","series-title":"Handbook of Dialysis","author":"Daugirdas","year":"2015"},{"issue":"7","key":"10.1016\/j.ijtb.2023.04.011_bib12","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2215\/CJN.00340118","article-title":"Clinical pharmacokinetics in kidney disease: fundamental principles","volume":"13","author":"Lea-Henry","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ijtb.2023.04.011_bib13","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/cpt.757","article-title":"The role of the kidney in drug elimination: transport, metabolism, and the impact of kidney disease on drug clearance","volume":"102","author":"Miners","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijtb.2023.04.011_bib14","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/17512433.2017.1323632","article-title":"Guidance to develop individual dose recommendations for patients on chronic hemodialysis","volume":"10","author":"Gotta","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ijtb.2023.04.011_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00583-19","article-title":"A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy","volume":"63","author":"Pistolesi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2023.04.011_bib16","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1592\/phco.29.5.562","article-title":"Antimicrobial dosing concepts and recommendations for critically Ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis","volume":"29","author":"Heintz","year":"2009","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.ijtb.2023.04.011_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000449029","article-title":"Advances in understanding and management of residual renal function in patients with chronic kidney disease","volume":"2","author":"Liu","year":"2016","journal-title":"Kidney Dis"},{"issue":"1","key":"10.1016\/j.ijtb.2023.04.011_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.18773\/austprescr.2016.008","article-title":"Prescribing for patients on dialysis","volume":"39","author":"Smyth","year":"2016","journal-title":"Aust Prescr"},{"key":"10.1016\/j.ijtb.2023.04.011_bib19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/jam.14478","article-title":"Recent updates on drug resistance in Mycobacterium tuberculosis","volume":"128","author":"Singh","year":"2020","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.ijtb.2023.04.011_bib20","series-title":"WHO Operational Handbook on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment","year":"2020"},{"key":"10.1016\/j.ijtb.2023.04.011_bib21","series-title":"Direktorat Jenderal Pencegahan dan Pengendalian Penyakit, Kementerian Kesehatan Republik Indonesia","year":"2020"},{"issue":"2","key":"10.1016\/j.ijtb.2023.04.011_bib22","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.924","article-title":"Antituberculosis drug-induced adverse events in the liver, kidneys, and blood: clinical profiles and pharmacogenetic predictors","volume":"104","author":"Hu","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ijtb.2023.04.011_bib23","first-page":"6","article-title":"Treatment of tuberculosis in renal disease","volume":"4","year":"2021","journal-title":"Guideline Version 4.0 [Internet]"},{"key":"10.1016\/j.ijtb.2023.04.011_bib24","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14740338.2018.1520837","article-title":"Moxifloxacin-induced QT interval prolongation and torsades de pointes: a narrative review","volume":"17","author":"Khan","year":"2018","journal-title":"Expet Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.ijtb.2023.04.011_bib25","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1080\/14740338.2019.1648429","article-title":"A safety evaluation of bedaquiline for the treatment of multi-drug resistant tuberculosis","volume":"18","author":"Cohen","year":"2019","journal-title":"Expet Opin Drug Saf"},{"issue":"13","key":"10.1016\/j.ijtb.2023.04.011_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.015969","article-title":"Use of qt prolonging medications by hemodialysis patients and individuals without end-stage kidney disease","volume":"9","author":"Assimon","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ijtb.2023.04.011_bib27","series-title":"Kucers' the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs","author":"Grayson","year":"2017"},{"issue":"3","key":"10.1016\/j.ijtb.2023.04.011_bib28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jcpt.13359","article-title":"Analysis of the risk factors of linezolid-related haematological toxicity in Chinese patients","volume":"46","author":"Dai","year":"2021","journal-title":"J Clin Pharm Therapeut"},{"issue":"1","key":"10.1016\/j.ijtb.2023.04.011_bib29","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06331-8","volume":"23","author":"Berry","year":"2022","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.ijtb.2023.04.011_bib30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ijtb.2023.04.011_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2229-516X.112228","article-title":"Bedaquiline: first FDA-approved tuberculosis drug in 40 years","volume":"3","author":"Mahajan","year":"2013","journal-title":"Int J Appl Basic Med Res"},{"issue":"9","key":"10.1016\/j.ijtb.2023.04.011_bib32","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/jac\/dku171","article-title":"Bedaquiline: a review of human pharmacokinetics and drug-drug interactions","volume":"69","author":"van Heeswijk","year":"2014","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.ijtb.2023.04.011_bib33","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1128\/AAC.01418-13","article-title":"Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug","volume":"58","author":"McLeay","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.ijtb.2023.04.011_bib34","doi-asserted-by":"crossref","first-page":"6934","DOI":"10.1021\/acsomega.0c06165","article-title":"Effect of disease state on the pharmacokinetics of bedaquiline in renal-impaired and diabetic rats","volume":"6","author":"Gour","year":"2021","journal-title":"ACS Omega"},{"key":"10.1016\/j.ijtb.2023.04.011_bib35","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.2147\/DDDT.S281639","article-title":"Profiling pretomanid as a therapeutic option for tb infection: evidence to date","volume":"15","author":"Stancil","year":"2021","journal-title":"Drug Design, Development and Therapy"},{"issue":"9","key":"10.1016\/j.ijtb.2023.04.011_bib36","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1128\/AAC.00112-09","article-title":"Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects","volume":"53","author":"Ginsberg","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijtb.2023.04.011_bib37","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Design, Development and Therapy"},{"issue":"7","key":"10.1016\/j.ijtb.2023.04.011_bib38","doi-asserted-by":"crossref","first-page":"493","DOI":"10.21037\/atm.2020.03.207","article-title":"Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?\u2014experience from a prospective observational study","volume":"8","author":"Fang","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.ijtb.2023.04.011_bib39","unstructured":"Ripamonti D, Cattaneo D, Sacco Hospital L, Antonio ID, Dai H, Copyright fpubh, et\u00a0al. Expert Consensus Statement on Therapeutic Drug Monitoring and Individualization of Linezolid."},{"issue":"1","key":"10.1016\/j.ijtb.2023.04.011_bib40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","article-title":"Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics","volume":"42","author":"Rao","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijtb.2023.04.011_bib41","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/jcph.968","article-title":"A review of moxifloxacin for the treatment of drug-susceptible tuberculosis","volume":"57","author":"Naidoo","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ijtb.2023.04.011_bib42","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1093\/jac\/dkx150","article-title":"Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?","volume":"72","author":"Maitre","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijtb.2023.04.011_bib43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/43.suppl_2.83","article-title":"Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man","volume":"43","author":"Stass","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.ijtb.2023.04.011_bib44","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1046\/j.0306-5251.2001.01557.x","article-title":"Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction","volume":"53","author":"Stass","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ijtb.2023.04.011_bib45","series-title":"Pedoman Diagnosis dan Peatalaksanaan di Indonesia. Edisi Revisi 3","year":"2021"},{"key":"10.1016\/j.ijtb.2023.04.011_bib46","series-title":"Levofloxacin","author":"Podder","year":"2022"},{"issue":"3","key":"10.1016\/j.ijtb.2023.04.011_bib47","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3897\/folmed.62.e48742","article-title":"Linezolid: a promising agent for the treatment of multiple and extensively drug-resistant tuberculosis","volume":"62","author":"Fermeli","year":"2020","journal-title":"Folia Med (Plovdiv)."},{"issue":"3","key":"10.1016\/j.ijtb.2023.04.011_bib48","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx147","article-title":"Clofazimine in nontuberculous mycobacterial infections: a growing niche","volume":"4","author":"McGuffin","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijtb.2023.04.011_bib49","series-title":"Basics of Pharmacology and Toxicology Volume 1: General and Molecular Pharmacology: Principles of Drug Action Introduction to Basics of Pharmacology and Toxicology","author":"Marshall","year":"2019"},{"issue":"3","key":"10.1016\/j.ijtb.2023.04.011_bib50","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0891-5520(05)70176-8","article-title":"Mycobacterial infections in patients with chronic renal disease","volume":"15","author":"Pien","year":"2001","journal-title":"Infect Dis Clin North Am"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570723000689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019570723000689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T08:04:28Z","timestamp":1747123468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019570723000689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":50,"alternative-id":["S0019570723000689"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2023.04.011","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on drug-resistant pulmonary tuberculosis treatment in hemodialysis patients","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2023.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}